Total Payments
$284,557
2024 Payments
$457.56
Companies
15
Transactions
296
Medicare Patients
24,465
Medicare Billing
$800,589
Payment Breakdown by Category
Consulting$135,261 (47.5%)
Research$110,329 (38.8%)
Travel$19,811 (7.0%)
Other$9,730 (3.4%)
Food & Beverage$8,430 (3.0%)
Education$995.83 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $135,261 | 52 | 47.5% |
| Unspecified | $110,329 | 2 | 38.8% |
| Travel and Lodging | $19,811 | 67 | 7.0% |
| Food and Beverage | $8,430 | 164 | 3.0% |
| Honoraria | $4,000 | 1 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,638 | 7 | 1.3% |
| Grant | $2,093 | 1 | 0.7% |
| Education | $995.83 | 2 | 0.3% |
Payments by Type
General
$174,228
294 transactions
Research
$110,329
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $112,429 | 3 | $0 (2021) |
| Gilead Sciences, Inc. | $71,596 | 126 | $0 (2024) |
| ViiV Healthcare Company | $66,786 | 84 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $18,607 | 32 | $0 (2021) |
| Theratechnologies Inc. | $7,553 | 12 | $0 (2019) |
| Merck Sharp & Dohme LLC | $1,910 | 3 | $0 (2022) |
| ABBVIE INC. | $1,832 | 15 | $0 (2022) |
| Janssen Products, LP | $1,540 | 3 | $0 (2022) |
| Janssen Research & Development, LLC | $1,194 | 7 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $1,000 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $457.56 | 6 | ViiV Healthcare Company ($364.14) |
| 2023 | $5,329 | 5 | ViiV Healthcare Company ($5,311) |
| 2022 | $18,191 | 30 | Gilead Sciences, Inc. ($9,414) |
| 2021 | $20,529 | 12 | Gilead Sciences, Inc. ($10,788) |
| 2020 | $133,460 | 20 | Eli Lilly and Company ($110,329) |
| 2019 | $28,926 | 63 | ViiV Healthcare Company ($14,006) |
| 2018 | $32,393 | 71 | Gilead Sciences, Inc. ($19,091) |
| 2017 | $45,271 | 89 | Gilead Sciences Inc ($20,811) |
All Payment Transactions
296 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | Valneva Usa, Inc. | IXCHIQ (Drug) | Food and Beverage | Cash or cash equivalent | $14.37 | General |
| Category: Vaccine | ||||||
| 10/22/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: HIV | ||||||
| 09/24/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $132.42 | General |
| Category: HIV | ||||||
| 07/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $46.51 | General |
| 03/05/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $105.72 | General |
| 03/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.54 | General |
| 07/15/2023 | EMD Serono, Inc. | SEROSTIM (Drug) | Food and Beverage | Cash or cash equivalent | $18.48 | General |
| Category: Endocrinology | ||||||
| 04/25/2023 | ViiV Healthcare Company | DOVATO (Drug) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: HIV | ||||||
| 03/09/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $57.11 | General |
| 03/09/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $34.27 | General |
| 03/09/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $19.37 | General |
| 12/07/2022 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $343.70 | General |
| 12/07/2022 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $54.00 | General |
| 11/02/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,710.00 | General |
| 10/23/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $119.55 | General |
| 10/22/2022 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $124.78 | General |
| Category: HIV | ||||||
| 10/22/2022 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $46.47 | General |
| Category: HIV | ||||||
| 09/29/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $117.90 | General |
| 09/20/2022 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 09/07/2022 | ViiV Healthcare Company | — | Food and Beverage | Cash or cash equivalent | $120.22 | General |
| 08/15/2022 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $278.05 | General |
| 08/15/2022 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $44.94 | General |
| 08/12/2022 | ViiV Healthcare Company | — | Food and Beverage | Cash or cash equivalent | $90.78 | General |
| 08/12/2022 | ViiV Healthcare Company | — | Food and Beverage | Cash or cash equivalent | $64.21 | General |
| 08/12/2022 | ViiV Healthcare Company | — | Food and Beverage | Cash or cash equivalent | $58.23 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $110,329 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 31 | 54 | $13,102 | $3,511 |
| 2022 | 3 | 92 | 116 | $14,100 | $6,714 |
| 2021 | 7 | 24,321 | 24,541 | $1.3M | $788,257 |
| 2020 | 1 | 21 | 26 | $5,538 | $2,106 |
Total Patients
24,465
Total Services
24,737
Medicare Billing
$800,589
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 54 | $13,102 | $3,511 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 51 | $10,863 | $4,022 | 37.0% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 39 | 39 | $1,677 | $1,619 | 96.6% |
| 0053A | Adm sarscv2 30mcg trs-sucr 3 | Office | 2022 | 26 | 26 | $1,560 | $1,073 | 68.8% |
| 0002A | Adm sarscov2 30mcg/0.3ml 2nd | Office | 2021 | 6,967 | 7,033 | $421,980 | $265,848 | 63.0% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 6,931 | 7,021 | $301,303 | $217,567 | 72.2% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 4,857 | 4,885 | $293,100 | $161,915 | 55.2% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 3,885 | 3,908 | $167,164 | $85,587 | 51.2% |
| 0031A | Adm sarscov2 vac ad26 .5ml | Office | 2021 | 1,584 | 1,584 | $95,040 | $50,815 | 53.5% |
| 0064A | Fee covid-19 vac 7 res | Office | 2021 | 78 | 78 | $3,354 | $3,277 | 97.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 32 | $6,816 | $3,249 | 47.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 26 | $5,538 | $2,106 | 38.0% |
About Dr. Gregory Huhn, M.D
Dr. Gregory Huhn, M.D is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366552952.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Huhn, M.D has received a total of $284,557 in payments from pharmaceutical and medical device companies, with $457.56 received in 2024. These payments were reported across 296 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($135,261).
As a Medicare-enrolled provider, Huhn has provided services to 24,465 Medicare beneficiaries, totaling 24,737 services with total Medicare billing of $800,589. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Chicago, IL
- Active Since 08/30/2006
- Last Updated 04/26/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1366552952
Products in Payments
- DOVATO (Drug) $18,080
- EDURANT (Drug) $9,397
- Epclusa (Drug) $8,952
- PREZISTA (Drug) $8,260
- EGRIFTA (Drug) $7,553
- TIVICAY (Drug) $5,933
- Biktarvy (Drug) $5,570
- Veklury (Drug) $3,150
- Mavyret (Drug) $1,777
- SYMTUZA (Drug) $1,303
- PREZCOBIX (Drug) $284.10
- Descovy (Drug) $195.93
- RUKOBIA (Drug) $132.42
- APRETUDE (Biological) $126.00
- CABENUVA (Biological) $66.04
- MAVYRET (Drug) $55.51
- Symtuza (Drug) $39.99
- TRIUMEQ (Drug) $26.47
- BEXSERO (Biological) $26.06
- SEROSTIM (Drug) $18.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247